Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

SK bioscience and Vaxxas Enter Joint Development Agreement

Thursday, August 24, 2023

SK bioscience and Vaxxas have forged a joint development agreement.  The collaboration represents a significant advancement in the field of vaccine delivery.

As per the terms of the agreement, SK bioscience is designated to provide the antigen employed in its typhoid conjugate vaccine, known as SKYTyphoid™. This particular vaccine is the result of a collaborative effort between SK bioscience and the International Vaccine Institute (IVI).

By utilising Vaxxas' HD-MAP technology to deliver the typhoid vaccine, the collaboration aims to make immunisation more accessible, efficient, and effective in regions where typhoid fever is a significant health concern.

The partnership aims to address challenges associated with the distribution and administration of vaccines, particularly in low- and middle-income countries where access to healthcare infrastructure may be limited.

Typhoid fever is a serious illness that often affects countries with lower incomes. But using vaccines for typhoid is tough because the vaccines need to work well even when it's really hot or cold. They also should be easy to use without needing a doctor. This partnership with Vaxxas gives a chance to solve these problems.  

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024